31545-26-3

Basic information

• Product Name: 4-CHLORO-3-NITROPHENYL CYCLOPROPYL KETONE
• Synonyms: 4-CHLORO-3-NITROPHENYL CYCLOPROPYL KETONE;TIMTEC-BB SBB009932;4-Chloro-3-nitrophenylcyclopropyl ketone, GC 99%;4-CHLORO-3-NITROPHENYL CYCLOPR;4-CHLORO-3-NITROPHENYL CYCLOPROPYL KETONE,99+%
• CAS NO: 31545-26-3
• Molecular Formula: C₁₀H₈ClNO₃
• Molecular Weight: 225.63
• EINECS: 250-690-4
• Mol File: 31545-26-3.mol
• Article Data: 3

Chemical Properties

• Melting Point: 78-80 °C
• Boiling Point: 333.4°Cat760mmHg
• Flash Point: 155.4°C
• Appearance: /
• Density: 1.464g/cm³
• Vapor Pressure: 0.000137mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-CHLORO-3-NITROPHENYL CYCLOPROPYL KETONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-3-NITROPHENYL CYCLOPROPYL KETONE(31545-26-3)
• EPA Substance Registry System: 4-CHLORO-3-NITROPHENYL CYCLOPROPYL KETONE(31545-26-3)

Safety Data

• Statements: 43
• Safety Statements: 24/25-36/37
• Hazardous Substances Data: 31545-26-3(Hazardous Substances Data)

Usage

Chemical Properties

light yellow crystalline powder

InChI:InChI=1/C10H8ClNO3/c11-8-4-3-7(5-9(8)12(14)15)10(13)6-1-2-6/h3-6H,1-2H2

Upstream product

• 6640-25-1 4-chlorophenyl cyclopropyl ketone 

Downstream Products

• 1402938-03-7 tert-butyl (2Z)-3-(4-chloro-3-nitrophenyl)-3-cyclopropylacrylate 
• 1402937-07-8 tert-butyl (2E)-3-(4-chloro-3-nitrophenyl)-3-cyclopropylacrylate 
• 1402936-61-1 BAY 1101042 
• 1402937-56-7 tert-butyl (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate 
• 1402937-57-8 tert-butyl 3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}-phenyl)-3-cyclopropylpropanoate 
• 1402937-10-3 tert-butyl 3-(3-amino-4-chlorophenyl)-3-cyclopropylpropanoate 

Relevant articles and documents

Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)

Herein we describe the discovery, mode of action, and preclinical characterization of the soluble guanylate cyclase (sGC) activator runcaciguat. The sGC enzyme, via the formation of cyclic guanosine monophoshphate, is a key regulator of body and tissue homeostasis. sGC activators with their unique mode of action are activating the oxidized and heme-free and therefore NO-unresponsive form of sGC, which is formed under oxidative stress. The first generation of sGC activators like cinaciguat or ataciguat exhibited limitations and were discontinued. We overcame limitations of first-generation sGC activators and identified a new chemical class via high-throughput screening. The investigation of the structure-activity relationship allowed to improve potency and multiple solubility, permeability, metabolism, and drug-drug interactions parameters. This program resulted in the discovery of the oral sGC activator runcaciguat (compound 45, BAY 1101042). Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy.

Synthesis and anthelminthic acitivity of alkyl-(5-acyl-1-benzimidazol-2-yl) carbamates

A series of alkyl-(5-acyl-l-H-benzimidazol-2-yl)-carbamates were prepared and screened for anthelminthic activity. Some of them were found to be fully active at low, atoxic oral dose levels against gastro-intestinal nematodes. The activity against Syphacia muris and Strongyloides ratta is indicated. From these studies methyl (5-benzoyl-1-H-benzimidazol-2-yl) carbamate (mebendazole) and methyl [5-(4-fluorobenzoyl)-1-H-benzimidazol-2-yl]carbamate (flubendazole) were selected for detailed investigation.